Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation
Original languageEnglish
Pages (from-to)15 - 21
Number of pages7
JournalMenopause
Volume20
Issue number1
DOIs
Publication statusPublished - 2013

Cite this

@article{facee2673ed745f091dedfc64081a27b,
title = "Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis",
abstract = "Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation",
author = "Bell, {Robin Jean} and Pam Fradkin and Schwarz, {Max Allan} and Davis, {Susan Ruth}",
year = "2013",
doi = "10.1097/gme.0b013e3182610cab",
language = "English",
volume = "20",
pages = "15 -- 21",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

TY - JOUR

T1 - Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis

AU - Bell, Robin Jean

AU - Fradkin, Pam

AU - Schwarz, Max Allan

AU - Davis, Susan Ruth

PY - 2013

Y1 - 2013

N2 - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation

AB - Investigate the extent of discontinuation of oral adjuvant endocrine therapy (OAET) in women nearly 4 years from the diagnosis of their first episode of invasive breast cancer and the reasons for such discontinuation

UR - http://www.ncbi.nlm.nih.gov/pubmed/22948136

U2 - 10.1097/gme.0b013e3182610cab

DO - 10.1097/gme.0b013e3182610cab

M3 - Article

VL - 20

SP - 15

EP - 21

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -